Salubris(SZ:002294) Zheng Quan Zhi Xing·2025-08-19 16:22Core Viewpoint - Shenzhen Xinlitai Pharmaceutical Co., Ltd. held its 13th meeting of the 6th Board of Directors on August 18, 2025, where several key reports were approved, including the 2025 semi-annual report and a special report on the use of raised funds [1][2]. Group 1: Meeting Resolutions - The Board unanimously approved the 2025 semi-annual report and its summary, which had already been reviewed by the Audit Committee [1][2]. - The Board also unanimously approved the special report on the storage and use of raised funds for the first half of 2025, which was similarly reviewed by the Audit Committee [2]. - The Board agreed to participate as a limited partner in the subscription of shares in the Shenzhen Songhe Capital Management Co., Ltd. managed private equity fund, with a total fundraising scale not exceeding 1.5 billion yuan, and the company committing up to 50 million yuan [3].